Ascendis Phase III Data Gives TransCon PTH An Edge In Hypoparathyroidism

The firm plans to submit to the US FDA in the third quarter and with the European Medicines Agency in the fourth quarter based on positive Phase III study results.

Soccer Goal — A Phase III trial for Ascendis' drug was positive • Source: Alamy

More than three-quarters of patients with hypoparathyroidism (HP) treated with Ascendis Pharma A/S’s TransCon PTH in a Phase III trial were able to stop taking conventional therapy, a potential point of differentiation in the market.

The company announced on 13 March that a Phase III trial testing TransCon PTH in HP patients met its primary...